参考文献/References:
[1] 宋国祥,吴中耀.眼眶病学[M].北京:人民卫生出版社,1999:212-223.
[2] Donaldson SS, Bagshaw MA, Kriss JP. Supervoltage orbital radio-therapy for Graves’ ophthalmopathy[J]. J Clin Endocrinol Metab, 1973, 37(2):276-285.
[3] Olivotto IA, Ludgate CM, Allen LH, et al. Supervoltage radiotherapy for Graves’ ophthalmopathy:CCABC technique and results[J]. Int J RadiatOncol Biol Phys, 1985, 11(12):2085-2090.
[4] Prummel MF, Mourits MP, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves’ ophthal-mopathy[J]. Lancet, 1993, 342(8877):949-954.
[5] Harris MA, Realini T, Hogg JP, et al. CT dimensions of the lacrimal gland in Graves orbitopathy[J]. Ophthal Plast Reconstr Surg, 2012, 28(1):69-72.
[6] 黑砚,康莉,李月月,等.甲状腺相关眼病眼眶组织的病理改变[J].中华眼科杂志,2008,44(5):423-426.
[7] Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ ophthalmopathy[J]. J Clin Endocrinol Metab, 2004, 89(1):15-20.
[8] Mourits MP, van Kempen-Harteveld ML, García MB, et al. Radio-therapy for Graves’ orbitopathy:randomised placebo-controlled study[J]. Lancet, 2000, 355(9214):1505-1509.
[9] Gripp S, Doeker R, Glag M, et al. Conventional and virtual simulation in retrobulbar irradiation[J]. Strahlenther Onkol, 2000, 176(3):131-134.
[10] Katz HR, Danoff B, Kramer S. Computerized orbital tomography in the radiotherapeutic treatment planning of graves’ ophthalmopathy[J]. Int J RadiatOncol Biol Phys, 1977, 2 Suppl 2:S150.
[11] Dagi LR, Zoumalan CI, Konrad H, et al. Correlation between extraoc-ular muscle size and motility restriction in thyroid eye disease[J]. Ophthal Plast Reconstr Surg, 2011, 27(2):102-110.
[12] Nguyen NP, Krafft SP, Vos P, et al. Feasibility of tomotherapy for Graves’ ophthalmopathy:Dosimetry comparison with conventional radiotherapy[J]. Strahlenther Onkol, 2011, 187(9):568-574.
[13] Espinoza S, Saboori M, Forman S, et al. Use of stereotactic intensity-modulated radiotherapy in thyroid-related ophthalmopathy. Case report[J]. J Neurosurg, 2004, 101 suppl3:S396-401.
[14] Lee VH, Ng SC, Choi CW, et al. Comparative analysis of dosimetric parameters of three different radiation techniques for patients with Graves’ ophthalmopathy treated with retro-orbital irradiation[J]. Radiat Oncol, 2012, 7(1):199.
[15] Wakelkamp IM, Tan H, Saeed P, et ah Orbital irradiation for Graves’ ophthalmopathy:Is it safe? A long-term follow-up study[J]. Ophthalmology, 2004, 111(8):1557-1562.
[16] Matthiesen C, Thompson JS, Thompson D, et al. The efficacy of radiation therapy in the treatment of Graves’ orbitopathy[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):117-123.
[17] Heyd R, Seegenschmiedt MH, Strassmann G, et al. Radiotherapy for Graves’ orbitopathy:results of a national survey[J]. Strahlen-ther Onkol, 2003, 179(6):372-376.
[18] Kahaly GJ, R?sler HP, Pitz S, et al. Low-versus high-dose radiotherapy for Graves’ ophthalmopathy:a randomized, single blind trial[J]. J Clin Endocrinol Metab, 2000, 85(1):102-108.
[19] Gerling J, Kommerell G, Henne K, et al. Retrobulbar irradiation for thyroid-associated orbitopathy:double-blind comparison between 2.4 and 16 Gy[J]. Int J Radiat Oncol Biol Phys, 2003, 55(1):182-189.
相似文献/References:
[1]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[2]杜芳芳,郭阳,姜炜.脑转移瘤的放射治疗进展[J].国际放射医学核医学杂志,2015,39(4):328.[doi:10.3760/cma.j.issn.1673-4114.2015.04.012]
Du Fangfang,Guo Yang,Jiang Wei.Advances in radiotherapy of brain metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):328.[doi:10.3760/cma.j.issn.1673-4114.2015.04.012]
[3]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[4]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
[5]薛秀青,苏成海.99Tc-亚甲基二膦酸盐的临床应用研究进展[J].国际放射医学核医学杂志,2010,34(5):285.[doi:10.3760/cma.j.issn.1673-4114.2010.05.008]
XUE Xiu-qing,SU Cheng-hai.Progress of 99Tc-methylenediphosphonate in clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):285.[doi:10.3760/cma.j.issn.1673-4114.2010.05.008]
[6]王任飞,谭建,张桂芝,等.131I治疗对Graves眼病转归的影响[J].国际放射医学核医学杂志,2011,35(4):223.[doi:10.3760/cma.j.issn.1673-4114.2011.04.007]
WANG Ren-fei,TAN Jian,ZHANG Gui-zhi,et al.Effect of 131I therapy on outcomes of Graves’ ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):223.[doi:10.3760/cma.j.issn.1673-4114.2011.04.007]
[7]段炼,陆克义,陈霞,等.131I治疗Graves病对甲状腺相关眼病转归的相关因素分析[J].国际放射医学核医学杂志,2011,35(4):230.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
DUAN Lian,LU Ke-yi,CHEN Xia,et al.Related factors of thyroid-associated ophthalmopathy in patents with Graves’ disease after 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):230.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
[8]杨宝军,李险峰,陆克义,等.99Tcm-二亚乙基三胺五乙酸与99Tcm-奥曲肽眼眶显像在甲状腺相关性眼病中的对比研究[J].国际放射医学核医学杂志,2009,33(1):22.[doi:10.3760/cma.j.issn.1673-4114.2009.01.022]
YANG Bao-jun,LI Xian-feng,LU Ke-yi,et al.A comparative study of 99Tcm-diethylene triaminepentaacetic acid and 99Tcm-octreotide orbital scan in thyroid associated ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(2):22.[doi:10.3760/cma.j.issn.1673-4114.2009.01.022]
[9]郭树龙,张久君.相对低剂量甲泼尼龙联合99Tc-MDP治疗老年Graves眼病的疗效观察[J].国际放射医学核医学杂志,2009,33(5):287.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.010]
GUO Shu-long,ZHA NG Jiu-jun.Efficacy of combined 99Tc-methylenediphosphonate and lower-dose meth ylprednisolone in the treatment of old patients with moderate-to-severe Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(2):287.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.010]
[10]曾志,袁卫红.甲状腺性眼病患者外周血细胞因子的研究[J].国际放射医学核医学杂志,2008,32(6):332.
ZENG Zhi,YUAN Wei-hong.Research of peripheral cytokine level in thyroid eye disease patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):332.